Leslie L. Popplewell, M.D.
- Lymphoma
- Lymphoma
- Associate Professor, Department of Hematology & Hematopoietic Cell Transplantation
- Atlanta Referring Physicians Phone
- Atlanta Referring Physicians Fax
(770) 400-6900
- Atlanta Referring Physicians Email
[email protected]
Leslie L. Popplewell, M.D., is the chief of Hematology, at City of Hope® Cancer Center Atlanta.
A trailblazer in her field, Dr. Popplewell has been performing bone marrow and stem cell transplants since 1997, and was working with CAR T-cells since before their FDA-approval in 2017. “It has been very inspiring to see them move from an exciting concept to an effective therapy used for thousands of people every year,” she says.
Dr. Popplewell sees patients with a wide range of blood cancers, including lymphoma, myeloma and leukemia, and helps to complete diagnoses on patients with suspected blood-related cancers. She also serves as the principal investigator for a number of clinical trials examining new lymphoma therapies, including CAR T-cells, and phase 1 and first-in-human trials. In addition, she is working on advanced transplant techniques for patients whose lymphoma has recurred.
Dr. Popplewell received her medical degree from the University of Louisville School of Medicine. She joined City of Hope in 1998 following a fellowship at Memorial Sloan Kettering Cancer Center in New York City. She is a member of the American Society of Hematology, the American Society of Clinical Oncology and the American Society for Transplantation and Cellular Therapy.
Location
Atlanta Cancer Center
Newnan, GA 30265
Education & Experience
Board Certifications
- Board Certification, Internal Medicine
- Board Certification, Hematology
Degrees
- M.D., F.A.C.P.
- 1988–1992, University of Louisville School of Medicine, Louisville, Kentucky, M.D., Internal Medicine
- 1984–1988, University of Kentucky, Lexington, Kentucky, B.S., Biology
Fellowship
- 1998–2000, Fellowship, Bone Marrow Transplantation, City of Hope, Duarte, CA
- 1995–1998, Fellowship, Medical Oncology and Hematology, Memorial Sloan-Kettering Cancer Center, New York, NY
Residency
- 1992–1995, Residency, Internal Medicine, Temple University Hospital, Philadelphia, Pennsylvania
Professional Experience
- 2023–present, Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation; Medical Director, Hematology and Blood and Marrow Transplant, City of Hope, Atlanta, GA
- 2020–present, Chief, Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
- 2018–Present, Co-Director, The Judy and Bernard Briskin Center for Clinical Research, City of Hope, Duarte, CA
- 2010–Present, Associate Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
- 2000–2010, Assistant Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
Awards & Memberships
Awards
- 2006–2007, Recipient, Tim Nesvig Lymphoma Fellowship Award
- 2000, Recipient, Lymphoma Research Foundation Association Research Grant
- 1999–2000, Recipient, Amgen Oncology Fellow Award
- 1997, Recipient, Merit Award, American Society of Clinical Oncology
- 1997, Board Eligible, Oncology and Hematology
- 1996–1997, Chief Fellow, Memorial Sloan Kettering Cancer Center
- 1996–1997, Recipient, Mortimer Lacher Fellowship
- 1996, Recipient, Merit Award, American Society of Hematology
- 1995, Recipient — Louis J. Treton Award — Most Outstanding 3rd Year Resident
Publications
Song, J. Y., Perry, A. M., Herrera, A. F., Chen, L., Skrabek, P., Nasr, M. R., Ottesen, R. A., Nikowitz, J., Bedell, V., Murata-Collins, J., Li, Y., McCarthy, C., Pillai, R., Wang, J., Wu, X., Zain, J., Popplewell, L., Kwak, L. W., Nademanee, A. P., … Weisenburger, D. D. (2021). Double-hit signature with TP53 abnormalities predicts poor survival in patients with germinal center type diffuse large B-cell lymphoma treated with R-CHOP. Clinical Cancer Research, 27(6), 1671–1680. https://doi.org/10.1158/1078-0432.CCR-20-2378
Gopal, A. K., Levy, R., Houot, R., Patel, S. P., Popplewell, L., Jacobson, C., Mu, X. J., Deng, S., Ching, K. A., Chen, Y., Davis, C. B., Huang, B., Fly, K. D., Thall, A., Woolfson, A., & Bartlett, N. L. (2020). First-in-human study of utomilumab, a 4-1BB/CD137 agonist, in combination with rituximab in patients with follicular and other CD20+ non-Hodgkin lymphomas. Clinical Cancer Research, 26(11), 2524–2534. https://doi.org/10.1158/1078-0432.CCR-19-2973
Siddiqi, T., Wang, X., Palmer, J., Popplewell, L. L., Nikolaenko, L., Herrera, A. F., Budde, L. E., Lim, L., Vyas, V., Brown, C. E., Forman, S. J., et al. (2019). CD19-targeting CAR-T cell therapy in CNS lymphoma [Conference abstract]. Blood, 134(Suppl 1), 4075. https://doi.org/10.1182/blood-2019-123765
Straus, D. J., Jung, S.-H., Pitcher, B., Kostakoglu, L., Grecula, J. C., Hsi, E. D., Schöder, H., Popplewell, L. L., Chang, J. E., Moskowitz, C. H., Wagner-Johnston, N., Leonard, J. P., Friedberg, J. W., Kahl, B. S., Cheson, B. D., & Bartlett, N. L. (2018). CALGB 50604: Risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood, 132(10), 1013–1021. https://doi.org/10.1182/blood-2018-01-827246
Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., Kline, J., Roschewski, M., LaCasce, A., Collins, G. P., Tran, T., Lynn, J., Chen, J. Y., Volkmer, J.-P., Agoram, B., Huang, J., Majeti, R., Weissman, I. L., Takimoto, C. H., … Smith, S. M. (2018). CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. The New England Journal of Medicine, 379(18), 1711–1721. https://doi.org/10.1056/NEJMoa1807315
O’Connor, O. A., Pro, B., Pinter-Brown, L., Bartlett, N., Popplewell, L., Coiffier, B., Lechowicz, M. J., Savage, K. J., Shustov, A. R., Gisselbrecht, C., Jacobsen, E., Zinzani, P. L., Furman, R., Goy, A., Haioun, C., Crump, M., Zain, J. M., Hsi, E., Boyd, A., & Horwitz, S. (2011). Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study. Journal of Clinical Oncology, 29(9), 1182–1189. https://doi.org/10.1200/JCO.2010.29.9024